Retatrutide – 50mg

Retatrutide is a novel triple agonist peptide that acts on the GIP, GLP-1, and glucagon receptors,
offering a unique approach to metabolic and weight-regulation research.
It has been studied for its potential to improve insulin sensitivity, enhance energy expenditure,
and support body composition research.
The 50mg vial provides a potent and consistent format for advanced metabolic investigations.

Potential Research Benefits

• Studied for metabolic and energy regulation
• Explored for weight management and lipid metabolism
• Supports insulin sensitivity and glucose balance research
• Triple agonist targeting GIP, GLP-1, and glucagon pathways

Scientific Background

Retatrutide is a next-generation multi-receptor peptide designed to activate three major metabolic pathways
simultaneously: GIP (glucose-dependent insulinotropic polypeptide),
GLP-1 (glucagon-like peptide-1), and glucagon receptors.
By engaging these systems, research suggests Retatrutide may influence energy balance,
lipid oxidation, and glycemic control.
It is currently under investigation for its potential to enhance metabolic efficiency
and promote favorable body composition in preclinical settings.

Product Details

• Compound: Retatrutide
• Form: Lyophilized Powder
• Amount: 50mg per vial
• Purity: ≥99%
• Appearance: White to off-white powder
• Research Use Only: Not for human consumption